Connext is developing recombinant TLR5 agonists and collagenase-based therapeutics to prevent side effects from cancer and radiation treatments, specifically targeting acute graft-versus-host disease and oral mucositis. The company aims to enhance patient quality of life by addressing the complications associated with immuno-oncology and regenerative medicine.
Funding
$22.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer and radiation treatments often lead to debilitating side effects, such as acute graft-versus-host disease and oral mucositis, significantly diminishing a patient's quality of life. Current treatment options are limited in their ability to prevent or effectively manage these complications arising from immuno-oncology and regenerative medicine approaches.
Solution
Connext is a clinical-stage biopharmaceutical company developing innovative therapeutics to mitigate side effects associated with cancer and radiation treatments. Their lead candidate, CNT101, is a recombinant TLR5 agonist designed to prevent acute graft-versus-host disease and oral mucositis. Additionally, Connext is developing CNT201, a first-in-class recombinant collagenase, for indications such as Dupuytren's contracture. By leveraging these two technology platforms, Connext aims to expand its pipeline in immuno-oncology and regenerative medicine, ultimately improving patient outcomes and quality of life.
Target Audience
The primary target audience includes patients undergoing cancer and radiation therapies, as well as individuals suffering from conditions such as acute graft-versus-host disease, oral mucositis, and Dupuytren's contracture.
Features
- CNT101: Recombinant TLR5 agonist in clinical development for the prevention of acute graft-versus-host disease and oral mucositis.
- CNT201: Recombinant collagenase in clinical development for the treatment of Dupuytren's contracture, with potential applications in Peyronie's disease, cellulite, and burn debridement.
- GMP manufacturing capabilities for the production of clinical-grade biologics.
- CDMO services for microbial-based recombinant proteins and pDNA.
- Pipeline expansion strategy focused on immuno-oncology and regenerative medicine.